Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + pyrotinib
- Development stage
- Phase 3
- Lead developer
- RemeGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of disitamab vedotin (RC48) and pyrotinib. Disitamab vedotin is an antibody-drug conjugate (ADC) developed by RemeGen, featuring a humanized anti-HER2 monoclonal antibody (hertuzumab) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. Pyrotinib, developed by Hengrui Medicine, is an orally available, irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) that targets HER1 (EGFR), HER2, and HER4. The combination is currently being evaluated in Phase II clinical trials, such as those led by The First Affiliated Hospital with Nanjing Medical University, as a neoadjuvant treatment for patients with previously untreated HER2-positive early breast cancer. Preclinical evidence suggests that pyrotinib may enhance the efficacy of disitamab vedotin by upregulating HER2 expression on the tumor cell surface, thereby facilitating increased ADC binding and internalization.
- Brand names
- Irely
- Other names
- RC48-ADCRC-48-ADCRC 48-ADChertuzumab vedotindisitamb vedotin + pyrotinib
02
Targets
EGFR (Epidermal growth factor receptor)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on disitamab vedotin + pyrotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + pyrotinib.